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Summary
Mitochondria are pleomorphic organelles [1, 2] that have
central roles in cell physiology. Defects in their localization
and dynamics lead to human disease [3–5]. Myosins are
actin-based motors that power processes such as muscle
contraction, cytokinesis, and organelle transport [6]. Here
we report the initial characterization of myosin-XIX (Myo19),
the founding member of a novel class of myosin that associ-
ates with mitochondria. The 970 aa heavy chain consists of
a motor domain, three IQ motifs, and a short tail. Myo19
mRNA is expressed in multiple tissues, and antibodies to
human Myo19 detect anw109 kDa band in multiple cell lines.
Both endogenous Myo19 and GFP-Myo19 exhibit striking
localization to mitochondria. Deletion analysis reveals that
the Myo19 tail is necessary and sufficient for mitochondrial
localization. Expressing full-length GFP-Myo19 in A549 cells
reveals a remarkable gain of function where the majority of
the mitochondria move continuously. Moving mitochondria
travel for many micrometers with an obvious leading end
and distorted shape. The motility and shape change are
sensitive to latrunculin B, indicating that both are actin
dependent. Expressing the GFP-Myo19 tail in CAD cells re-
sulted in decreased mitochondrial run lengths in neurites.
These results suggest that this novel myosin functions as
an actin-based motor for mitochondrial movement in verte-
brate cells.
Results and Discussion
Myo19 Encodes a Novel Metazoan Myosin
Previous sequence analysis predicted an uncharacterized
myosin gene on human chromosome 17q12 that appeared to
represent a novel myosin class [7, 8]. With the database
sequence FLJ22865 (myohd1, GI: 14286205), we generated
polymerase chain reaction (PCR) primers to clone the full-
length coding region of this putative myosin from human
pancreas cDNA. Sequence analysis of the PCR-amplified*Correspondence: oaq100@psu.educlone revealed a 970 aa coding region consisting of a myosin
motor domain, a neck region containing three IQ motifs, and
a short tail (Figure 1A). The Myo19 motor domain shares
w35% sequence identity with the motor domains of human
skeletal muscle myosin, Myo5a, and Myo6. The motor con-
tains the conserved GESGAGKT sequence from the P loop,
DXXGFE sequence from switch-2 (DVYGFE), and a slightly
divergent MEAFGNACTLRNNNSSRFGK in the switch-1 region
(see Figure S1A available online; reviewed in [9]). Myo19 has
a glutamine at the TEDS position, indicating that it is not regu-
lated by heavy-chain phosphorylation at this site [10]. The
three IQ motifs in the neck region are expected to bind calmod-
ulin or calmodulin-like light chains [11]. The 146 aa tail domain
is basic (pIw 9.2) and is not predicted to form a coiled coil [12].
Interestingly, the tail has no obvious sequence homology
with other proteins in the databases, except for other Myo19
orthologs (Figure S1B). FLJ22865 corresponds to a 770 aa
Myo19 sequence lacking four sequential exons from the
core motor domain and is thus likely to represent either an
aberrant cDNA or a splice form with a nonfunctional motor.
Clear orthologs of human Myo19 are present in multiple verte-
brate species including mouse (GI: 56206893), chicken (GI:
118100337), Xenopus laevis (GI: 62185680), and zebrafish
(GI: 189519181). At the amino acid level, human Myo19 (970
aa) exhibits 82% identity to mouse Myo19 (963 aa) and 56%
identity to Xenopus laevis Myo19 (971 aa). Although Myo19
arose early in metazoan evolution, it appears to have been
lost from lineages leading to Drosophila and C. elegans [8].
Myo19 Is Expressed in Multiple Tissues and Cell Lines
To determine the tissue expression pattern of Myo19, we
probed a northern blot with a sequence from the 30 noncoding
region. A band of approximately 4.2 kb was detected in
multiple tissues (Figure 1B). Analysis of expressed sequence
tag (EST) databases (Table S1) and the Allen Brain Atlas
(http://www.brain-map.org) indicate that Myo19 is broadly
expressed in vertebrate cells, tissues, and tumors. Antibodies
raised against the Myo19 peptide AKELDGVEEKHFS (aa 829–
841) detected a protein of the expected size of w109 kDa in
western blots of human and other primate cell lines (Figure 1C).
We also detected Myo19 in mouse cell lines (B16-F1 and CAD),
but the signal was weaker, likely because of sequence differ-
ences in the antibody target (SKELDGMEEKPMP in mouse).
Myo19 Localizes to Mitochondria
To determine the cellular localization of Myo19, we immuno-
stained multiple cell lines (A549, HeLa, and COS-7) with anti-
Myo19 antibody. Colocalization with MitoTracker-stained
mitochondria revealed clear and striking localization of endog-
enous Myo19 to mitochondria (Figure 2A; Figure S2A). To
determine the region of Myo19 required for mitochondrial
localization, we generated a series of GFP constructs con-
taining different regions of the Myo19 protein. Full-length
GFP-Myo19 and a ‘‘tail’’ construct containing amino acids
801–970 both clearly localized to mitochondria (Figure 2B;
Figure S2B). However, a construct containing the motor
domain and IQ motifs (aa 1–828) did not localize to mitochon-
dria and exhibited diffuse cytoplasmic staining with some
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Figure 1. Myo19 Is Expressed in Multiple Tissues and Cell Lines
(A) Human Myo19 is predicted to consist of a motor domain, a neck region
with three IQ motifs, and a short tail domain.
(B) A 4.2 kb messenger RNA encoding for the Myo19 protein was detected
by northern blot analysis in multiple human tissues at varying levels. In skel-
etal muscle, a larger mRNA also appeared to react with the probe. Although
the brain sample in this blot did not show strong reactivity, expressed
sequence tag (EST) databases indicate that Myo19 is expressed in brain.
Ladder indicates sizes of molecular weight markers in kb.
(C) A protein of approximately 109 kDa was detected by western blot anal-
ysis with antibodies raised against a peptide from the tail of human Myo19.
This antibody cross-reacted poorly with rodent cell lines (B16F1 and CAD)
but was able to detect Myo19 in human (HeLa and A549) and monkey
(COS-7) cell lines. Ladder indicates sizes of molecular weight markers in
kDa.
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Figure 2. Myo19 Localizes to Mitochondria
(A) Antibodies raised against a peptide from human Myo19 (green) strongly
label MitoTracker-stained mitochondria (red) in A549 cells (shown), HeLa
cells, and COS-7 cells.
(B) Both full-length GFP-Myo19 and a tail construct (green) also colocalize
with MitoTracker-labeled mitochondria (red) in HeLa cells (shown), A549
cells, and COS-7 cells. Constructs consisting of the motor domain and IQ
motifs do not localize to mitochondria.
(C) Amino acids 824–970 are necessary and sufficient for mitochondrial
localization because GFP constructs consisting of only this sequence of
amino acids localize to mitochondria.
GFP is represented by a green oval in the domain diagrams of the constructs
in (B) and (C). Scale bars in (A) and (B) represent 10 mm.
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2009brighter puncta (Figure 2B; Figure S2B). To test whether
Myo19 is anchored to the mitochondrial outer membrane via
insertion of a C-terminal transmembrane helix [13], we added
GFP to the C terminus [14]. Expression of either a Myo19 tail
or a full-length Myo19 construct GFP-tagged at the C terminus
resulted in mitochondrial localization. Taken together, these
data indicate that the tail domain of Myo19 is necessary and
sufficient for mitochondrial localization via a mechanism that
is unlikely to involve a C-terminal transmembrane helix (Fig-
ure 2C).
To test whether Myo19 is stably associated with mitochon-
dria, we used fluorescence recovery after photobleaching
(FRAP) analysis (Movie S1). GFP-Myo19 tail displayed
recovery dynamics similar to those of cytochrome b5 (GFP-
Cytob5-RR), a transmembrane protein that localizes to the
outer mitochondrial membrane [15] (Figure S3). Six minutes
following the bleaching event, neither construct recovered its
fluorescence completely (52% 6 7% recovery GFP-Myo19
tail, n = 16; 53% 6 4% GFP-cytob5-RR, n = 10), and both
constructs had a time to 50% maximum recovery (t1/2) of
greater than 2 min (Figure S3B). The lack of fluorescence
recovery cannot be accounted for by simple photofading
due to visualization of the samples, because unbleached
regions of the same or neighboring cells did not lose signifi-
cant amounts of fluorescence over the same time period.
Although the Myo19 tail shares no obvious sequence
homology with class I myosin tails, both Myo19 and class Imyosin tail regions contain a large number of basic residues.
In class I myosins, these basic residues mediate the binding
to specific phospholipids in the membrane [16]. Although it
is possible that binding to acidic phospholipids may anchor
Myo19 to mitochondria, it is unlikely that the Myo19 and Myo1
mechanisms are identical, because the FRAP dynamics of
Myo1A are much faster (w80% recovery in less than 1 min)
than those of Myo19 [17]. These data indicate that Myo19 does
not rapidly exchange and suggest that it is tightly associated
with the mitochondrial outer membrane.Expressing GFP-Myo19 Alters Mitochondrial Dynamics
To test whether Myo19 functions in actin-based mitochondrial
motility, we transfected A549 cells with GFP-Myo19, pDsRed2-
Mito (as a control), or both plasmids in combination and then
used time-lapse imaging to assess mitochondrial dynamics.
In control A549 cells, the vast majority of mitochondria re-
mained largely in place with only small ‘‘jostling’’ movements
(Movie S2). Expressing GFP-Myo19, however, led to a dramatic
increase in mitochondrial motility (Movie S3; Figure 3A). In
approximately 40% of the cells expressing GFP-Myo19, the
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Figure 3. Expressing GFP-Myo19 Increases Mitochondrial
Motility
(A) Mitochondria in control A549 cells expressing pDsRed2-
Mito showed little movement. Expression of GFP-Myo19
greatly increased mitochondrial movements and the lengths
of those movements. These movements were often nonlinear
and did not necessarily correspond to movements toward or
away from the nucleus. Arrows in the top panels represent
the initial direction of movement for the indicated mitochon-
dria, and paths taken by those mitochondria (over 4 min) are
represented in the bottom panel. Images are from Movie S2
for the control cell and Movie S3 for the GFP-Myo19-
expressing cell.
(B) In addition to inducing motility of mitochondria in A549
cells, expression of full-length GFP-Myo19 often led to mito-
chondria with an obvious taper, where the trailing end was
narrower than the leading end, as can be seen by phase-
contrast imaging or fluorescence imaging. Tapered mito-
chondria were only occasionally observed in cells not
expressing GFP-Myo19. Arrow indicates the direction of
movement.
(C) A histogram of velocities of randomly selected mitochon-
dria shows that expression of full-length GFP-Myo19 led to
an 80% increase in the average mitochondrial velocity (*p <
0.0003). For pDsRed2-Mito (control) cells, n = 121 mitochon-
dria (12 cells). For GFP-Myo19 cells, n = 153 mitochondria
(8 cells). Velocities in legend are mean 6 standard error of
the mean (SEM).
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2010majority of mitochondria moved continuously for many
micrometers with one end of the mitochondrion leading. The
leading end was often wider than the trailing end, resulting in
a tadpole-like appearance (Figure 3B; Movie S3). Unlike micro-
tubule-dependent movements, these mitochondrial move-
ments were neither linear nor obviously directed to or from
the cell center (Figure 3A; Movie S4).
To quantify the increase in mitochondrial motility induced by
GFP-Myo19, we determined a ‘‘displacement index’’ (DI) by
dividing the area over which the mitochondrial network moved
in a 3:20 (min:s) time lapse by the area occupied by mitochon-
dria in the first frame of the recording (Figure S4). If the mito-
chondrial network remained perfectly stationary, then DI = 1.
Control A549 cells had a DI of 1.2 6 0.1 (n = 10 cells), whereas
the DI in GFP-Myo19 cells increased by 75% to 2.1 6 0.7 (n =
28 cells, p < 0.0003; Figure S4D). Additionally, the values for DI
from cells expressing GFP-Myo19 alone were not statistically
different from the DI values calculated from cells expressing
both pDsRed2-Mito and GFP-Myo19 (2.2 6 0.16, n = 19 cells).
These data demonstrate that expression of GFP-Myo19
dramatically increases mitochondrial dynamics.
As an additional measure of mitochondrial motility, we also
calculated the average velocities of randomly selected mito-
chondria in control A549 cells and A549 cells transfected
with GFP-Myo19. The velocities of control mitochondria
formed a broad peak centered at relatively low velocities,
whereas the velocity distribution for GFP-Myo19 mitochondria
was shifted to the right and had an additional small peak in the
50–75 nm/s range (Figure 3C). The average velocity of
randomly selected mitochondria in the control cells was
16 6 1 nm/s (n = 121 mitochondria, 12 cells). Expressing
GFP-Myo19 resulted in an average velocity of 29 6 2 nm/s
(n = 153 mitochondria, 8 cells; p < 0.0001), an 80% increaseover control cells. Expression of GFP-Myo19 in conjunction
with pDsRed2-Mito also resulted in a similar increase in
velocity over control cells (31 6 2 nm/s, n = 62 mitochondria,
8 cells; p < 0.0001) and was not significantly different from cells
expressing GFP-Myo19 alone. Because these measurements
included mitochondria from all GFP-Myo19 cells, including
those that exhibited little movement, the average velocity in
the w40% of A549 cells that exhibited increased mitochon-
drial movement would be even greater. When velocities were
measured by selecting for mitochondria that were exhibiting
long-range, end-on movements, the mitochondria in GFP-
Myo19 cells that were moving continuously had an average
velocity of 73 6 3 nm/s (n = 125 mitochondria, 8 cells). In
control cells, the average of moving mitochondria was 102 6
7 nm/s (n = 27 mitochondria, 6 cells). These values are similar
to the value of the additional minor peak in the histograms of
velocities for randomly chosen mitochondria.
GFP-Myo19-Induced Mitochondrial Motility Is Actin
Dependent and Requires the Myo19 Motor Domain
We hypothesize that the movements of mitochondria we
observed are powered by interactions between the Myo19
motor domain and randomly organized actin filaments. To test
whether the observed gain of function requires the Myo19
motor domain, we measured the DI (Figure S4C) and average
velocity of mitochondria in A549 cells expressing GFP-Myo19
tail. Neither the DI (1.5 6 0.1, n = 17 cells) nor the velocity of
randomly chosen mitochondria (206 3 nm/s, n = 38 mitochon-
dria, 4 cells) was significantly different from those measures in
control cells. Similar results were also obtained in cells coex-
pressing GFP-Myo19 tail and pDsRed2-Mito (DI = 1.5 6 0.1,
n = 19 cells; 21 6 2 nm/s, n = 55 mitochondria, 8 cells). In
either case, expression of GFP-Myo19 tail did not increase
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Figure 4. GFP-Myo19-Induced Movements in A549 Cells Are Actin Depen-
dent, and Expression of GFP-Myo19 Tail Decreases Mitochondrial Run
Lengths in CAD Cells
(A) As can be seen in Movie S5, microtubule disruption with 15 mM nocoda-
zole failed to inhibit mitochondrial movements or shape change in GFP-
Myo19-expressing A549 cells (drug added at 1 min, 40 s). Arrows in the
top panels represent the initial direction of movement, and the correspond-
ing tracks over the next 4 min are shown in the bottom panels.
(B) Disruption of actin with the addition of 500 nM latrunculin B halted mito-
chondrial movements (drug added at 26:19).
(C) Latrunculin B also disrupted the tapered mitochondrial shape within
2 min of addition, as visualized by phase-contrast microscopy.
(D) Expression of GFP-Myo19 tail in differentiated CAD cells resulted in
a 40% decrease in mitochondrial run length in neurites, as compared to
control cells (*p < 0.03, n = 141 for pDsRed2-Mito control, n = 250 for
GFP-Myo19 tail). The average velocity of moving mitochondria was similar
in control cells (75 6 11 nm/s, n = 16) and in cells expressing GFP-Myo19
tail (65 6 5 nm/s, n = 69). Error bars represent SEM.
Images in (A) and (B) correspond to portions of Movie S5. Time stamp repre-
sents min:s.
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2011mitochondrial motility, indicating that the motor domain of
Myo19 is required for enhanced mitochondrial dynamics.
To test whether these movements are indeed actin based,
cells expressing full-length GFP-Myo19 were treated with
15 mM nocodazole to disrupt microtubules or 500 nM latrunculin
B to disrupt F-actin. This dose of nocodazole was sufficient to
disrupt the distribution of the endoplasmic reticulum within
5 min (data not shown). Mitochondrial movements induced by
GFP-Myo19 were insensitive to nocodazole treatments (Fig-
ure 4A;MoviesS5–S7).Thesemitochondriacontinued todisplay
movement over many micrometers, and the tadpole shape
remained. However, upon addition of latrunculin B to nocoda-
zole-treated cells, the end-on, directed movements ceased
(Figure 4B; Movies S5–S7). In addition, the mitochondria lost
their asymmetric shape within 2 min of latrunculin B treatment
(Figure 4C). Treatment of cells with latrunculin B without noco-
dazole pretreatment also resulted in a prompt cessation of
end-on mitochondrial movement and a rapid loss of the asym-
metric shape, demonstrating that both the motility and altered
shape are dependent on the presence of F-actin (Movie S9).
An alternative to the hypothesis that the motor activity of
Myo19 powers mitochondria movements would be that
Myo19 recruits F-actin to the mitochondria and actin polymer-
ization pushes the organelle via a mechanism similar to Listeria
motility [18–20]. However, mitochondria in GFP-Myo19-
expressing cells did not exhibit phase-dense tails similar to
those reported for Listeria (Figure 3B; Movies S4 and S6). To
determine whether GFP-Myo19-labeled mitochondria lack
actin tails, we coexpressed the nonperturbing F-actin label
mRFP-utrophin [21] in combination with full-length GFP-
Myo19. Although we observed mRFP-utrophin labeling of
other F-actin structures such as filopodia, we did not observe
F-actin tails behind GFP-Myo19-labeled mitochondria (Fig-
ure S5A; Movies S11 and S12). Additionally, we took time-lapse
movies of GFP-Myo19-expressing cells on gridded coverslips,
allowing us to locate cells with increased mitochondrial
dynamics prior to fixation and phalloidin staining. Again, the
mitochondria lacked Listeria-like actin tails (Figure S5B; Movie
S13). When GFP-utrophin-expressing A549 cells were infected
with fluorescentListeria, actin clouds and actin tails associated
with the bacteria (Figure S5C; Movie S14). Taken together,
these data indicate that Myo19-induced movement is unlikely
to be due to polymerization-mediated pushing.
Although the lack of directed mitochondrial movement in
control A549 cells was ideal for gain-of-function experiments,
it was problematic for loss-of-function studies. Because
expression of myosin tails has been widely used as a domi-
nant-negative approach to investigate the functions of uncon-
ventional myosins [22–24] and previous work has shown that
mitochondrial motility in neurites is partially actin based
[25–27], we expressed the Myo19 tail in CAD cells [28] to test
the function of Myo19 in normal mitochondrial dynamics. In
CAD cell neurites, where mean run lengths can be measured
relatively easily, expressing GFP-Myo19 tail resulted in a
40% decrease in mitochondrial run length from 1.4 6 0.3 mm
(n = 141) for control cell (pDsRed2-Mito-labeled) mitochondria
to 0.86 0.1 mm (n = 250) for GFP-Myo19 tail-labeled mitochon-
dria (Figure 4D, p < 0.03). This suggests that Myo19 function is
indeed necessary for normal mitochondrial dynamics.
Myo19 Is a Novel Mitochondrial-Associated Myosin that Is
Likely to Function in Actin-Based Mitochondrial Dynamics
Taken together, our data strongly suggest that Myo19 is
a broadly expressed mitochondrial myosin involved in actin-mediated mitochondrial movements and positioning. Endoge-
nous Myo19 localizes to mitochondria, and the FRAP and trun-
cation analyses indicate that Myo19 localizes to mitochondria
via its tail domain. Expression of full-length GFP-Myo19
protein induces a dramatic increase in mitochondrial motility
in A549 cells, and we observed similar increases in mitochon-
drial motility in COS-7 and B16-F1 cells (data not shown). As
predicted for myosin-driven movements, these movements
require the motor domain, because GFP-Myo19 tail
Current Biology Vol 19 No 23
2012expression did not result in the enhancement of mitochondrial
dynamics observed in cells expressing full-length GFP-
Myo19. Additionally, these movements are indeed actin
based, because GFP-Myo19-induced movements cease upon
destabilization of the actin network. Because the striking
increase in mitochondrial motility was not observed in 100%
of the cells expressing GFP-Myo19, it is likely that additional
factors regulate Myo19 function and/or mitochondrial move-
ment. Whether those conditions are related to the amount of
Myo19 on the mitochondrial surface or to the activation state
of Myo19 motor has yet to be determined. Expression of the
GFP-Myo19 tail may impact the activity level of Myo19 on
the mitochondrial surface by displacing endogenous, func-
tional Myo19. In CAD cell neurites, expression of GFP-Myo19
tail resulted in a 40% decrease in mitochondrial run lengths,
lending further support to the hypothesis that Myo19 is
involved in mitochondrial dynamics.
The localization and dynamics of mitochondria are critical
to their function, and disruption of these processes leads
to human disease [29, 30]. Mitochondrial localization and
dynamics have been shown to involve both microtubules
and actin [31–35]. However, the mechanism of actin-based
mitochondrial movements in vertebrates remains unclear
[36]. Our discovery of a novel class of myosin that localizes
to mitochondria provides a possible molecular mechanism
for actin-based mitochondrial movements.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures, five
figures, two tables, and fourteen movies and can be found online at http://
www.cell.com/current-biology/supplemental/S0960-9822(09)01845-4.
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